Trial Underway to Provide Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain...
Statement from Health Canada on the Testing of Cannabis for Medical Purposes for Unauthorized Pest Control Products OTTAWA, Feb. 7, 2017 /CNW/ – Recently, two licensed producers of cannabis...
CanniMed Therapeutics Inc. Provides Update on Patient Growth Rates, Sales Volume and Product Supply SASKATOON, Saskatchewan–(BUSINESS WIRE)–CanniMed Therapeutics Inc. (TSX:CMED) (“CMED” or the “Company”), a leading plant biopharmaceutical company...
Last week, James West of the Midas Letter published interviews of four CEOs of publicly-traded Canadian licensed producers, including Vic Neufeld of Aphria (TSXV: APH) (OTC: APHQF), Brent Zettl of...
Early trading in CanniMed Therapeutics (TSX: CMED) was disappointing, as the recent IPO broke its $12 offering price and traded below the $11.28 underwriters price. In the first half-hour...
Perhaps the biggest story of 2016 in the cannabis capital markets was the surge in prices and the amount of capital raised for the cannabis industry in Canada during...
CanniMed Therapeutics (TSX: CMED) priced its initial public offering at $12, selling 5mm shares through a syndicate led by AltaCorp Capital to raise $60mm. The underwriters, which also included Canaccord...
